Pure Global
NCT05763602

PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)

Intranasal Povidone Iodine (PVI) to Prevent Staphylococcus Aureus Surgical Site Infections After Operative Procedures to Fix High-Energy Lower Extremity Fractures (POTENT Study)
Loreen Herwaldt·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Surgical Site Infection
Drug/Device/Intervention
povidone-iodine topical ointment
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Loreen Herwaldt
Funder
University of Iowa
Location
Atlanta,Indianapolis,Iowa City,Saint Louis,Dallas,Salt Lake City, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Sep 15, 2022
End date
May 31, 2025
Enrollment
2000 participants
Primary outcome

Incidence of Complex (deep incisional or organ space) Staphylococcus aureus surgical site infection (SSI)

Summary

The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of
 patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation procedures of
 high-energy lower extremity fractures (HELEF) will decrease the patients' risk of surgical
 site infections (SSI), particularly those caused by Staphylococcus aureus.

ICD-10 classifications
Infection following a procedure, not elsewhere classifiedBacterial infection of unspecified siteOther bacterial infections of unspecified siteInfection of obstetric surgical woundOther specified local infections of skin and subcutaneous tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05763602
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05763602 through Pure Global AI's free database. This Phase 4 trial is sponsored by Loreen Herwaldt and is currently Recruiting. The study focuses on Surgical Site Infection. Target enrollment is 2000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.